FDA Alerts
Omnigraft Gains Approval
The U.S. Food and Drug Administration today approved a new indication for the Integra Omnigraft Dermal Regeneration Matrix (Omnigraft) to treat certain diabetic foot ulcers.
FDA: Don't Take Diamond 3500
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Diamond 3500, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
FDA Warns Against Sex Enhancement Pill
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Eros Power Zone 1900, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
ED Supplement May Pose Health Risk
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Triple MiracleZen Gold 1750 mg, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
Male Enhancement Product May Pose Health Risk
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Xtra Zone 2400, a product promoted and sold for sexual enhancement on various websites and in some retail stores.
Basaglar Gets FDA Green Light
The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Type 2 Diabetes Rx May Pose Serious Health Risks
An FDA safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections.
Joint Pain Warning for Diabetes Meds
The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling.
FDA: Diabetes Rx May Pose Serious Health Risk
The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.
New Treatment for Diabetic Retinopathy
The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema.